






























Supplementary Materials

S1 List of the 156 glycans screened.











Structures	Id.
Galβ1-3GlcNAcβ1-4Gal 	1
Galβ1-4GlcNAcβ1-4Gal 	2
Galβ1-3GlcNAc 	3
Galβ1-3GlcNAcβ1-3Galβ1-4Glc 	4
GlcNAcβ1-3Galβ1-4Glc 	5
Galβ1-4GlcNAcβ1-3Galβ1-4Glc 	6
Galβ1-4(GlcNAcβ1-3Galβ1-4)₂Glc 	7
Galβ1-4(GlcNAcβ1-3Galβ1-4)₃Glc 	8
Fucα1-2Gal 	9
Fucα1-2Galβ1-4Glc 	10











Fucα1-2Galβ1-3GlcNAcβ1-3Gal 	11
Fucα1-2Galβ1-4GlcNAcβ1-3Gal 	12
Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc 	13
Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4Glc 	14
GalNAcα1-3(Fucα1-2)Gal 	15
GalNAcα1-3(Fucα1-2)Galβ1-4Glc 	16
GalNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ1-3Gal 	17
GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ1-3Gal 	18
GalNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ1-3Galβ1-4Glc 	19











GalNAc α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc	20
Gal α 1-3(Fuc α 1-2)Gal β 1-4Glc	21
Gal α 1-3(Fuc α 1-2)Gal β 1-3GlcNAc β 1-3Gal	22
Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc β 1-3Gal	23
Gal α 1-3(Fuc α 1-2)Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc	24
Gal α 1-3(Fuc α 1-2)Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc	25
Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal	26
Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)Glc	27
Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal	28












Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Gal 	29
Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal 	30
Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc 	31
Fucα1-2Galβ1-3(Fucα1-4)GlcNAcβ1-3Gal 	32
Galβ1-4(Fucα1-3)Glc 	33
Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc 	34
Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc 	35
Neu5Acα2-3Galβ1-4(Fucα1-3)Glc 	36
Galα1-3Galβ1-4(Fucα1-3)Glc 	37
Fucα1-2Galβ1-4(Fucα1-3)Glc 	38

GalNAc α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-3)Glc	39
Gal α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-3)Glc	40
Gal α 1-3Gal β 1-4Glc	41
Gal α 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc	42
GalNAc β 1-3Gal α 1-3Gal β 1-4Glc	43
Gal β 1-3GalNAc β 1-3Gal α 1-3Gal β 1-4Glc	44
Gal α 1-3(Gal β 1-4GlcNAc β 1-3) ₂ Gal β 1-4Glc	45
Gal α 1-3(Gal β 1-4GlcNAc β 1-3) ₃ Gal β 1-4Glc	46
Gal α 1-3(Gal β 1-4GlcNAc β 1-3) ₄ Gal β 1-4Glc	47
Neu5Ac α 2-3Gal β 1-3GlcNAc β 1-3Gal	48
Neu5Ac α 2-3Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc	49







Neu5Acα2-3Galβ1-4GlcNAcβ1-3Gal 	50
Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc 	51
Neu5Acα2-6Galβ1-4Glc 	52
Neu5Acα2-3Galβ1-4Glc 	53
Neu5Acα2-8Neu5Acα2-3Galβ1-4Glc 	54
Neu5Acα2-8Neu5Acβ2-8Neu5Acα2-3Galβ1-4Glc 	55
GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc 	56
GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc 	57
GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc 	58
Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc 	59






Neu5Acα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glc 	60
Neu5Acα2-3Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc 	61
Galβ1-3GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc 	62
Neu5Acα2-8Neu5Acα2-3Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc 	63
Galβ1-3GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc 	64
Galβ1-3GalNAcβ1-4Galβ1-4Glc 	65
Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc 	66
GalNAcβ1-4Galβ1-4Glc 	67
Galβ1-4(Neu5Acα2-3)Galβ1-4Glc 	68
Galα1-4Galβ1-4Glc 	69











GalNAcβ1-3Galα1-4Galβ1-4Glc 	70
Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc 	71
Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc 	72
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc 	73
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc 	74
Galβ1-3GalNAc β1-3Gal 	75
Fucα1-2Galβ1-3GalNAcβ1-3Gal 	76
GalNAcα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Gal 	77
Galα1-3(Fucα1-2)Galβ1-3GalNAcβ1-3Gal 	78
Neu5Acα2-3Galβ1-3GalNAcβ1-3Gal 	79









Neu5Acα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc 	80
GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glc 	81
GalNAcα1-3GalNAcβ1-3Gal 	82
GalNAcα1-3GalNAcβ1-3Galα1-3Galβ1-4Glc 	83
GalNAcβ1-3Gal 	84
Galα1-3Gal 	85
Galα1-4Gal 	86
GlcNAcβ1-3Gal 	87
Neu5Acα2-3Gal 	88
Galβ1-4Glcβ1-1βGal 	89
Fucα1-2Galβ1-4Glcβ1-1βGalα2-1Fuc 	90








Neu5Ac α 2-3Gal β 1-4Glc β 1-1 β Gal α 2-3Neu5Ac	91
Fuc α 1-2Gal β 1-4(Fuc α 1-2)Glc	92
GalNAc α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-2)Glc	93
Gal α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-2)Glc	94
Neu5Ac α 2-3Gal α 1-4Gal β 1-4Glc	95
NeuAc α 2-8Neu5Ac α 2-3Gal β 1-3GlcNAc β 1-3Gal	96
Gal β 1-3GalNAc β 1-4Gal β 1-3GalNAc β 1-4Gal β 1-4Glc	97
GlcA β 1-3Gal β 1-4Glc	98
GlcA β 1-3Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc	99
Gal β 1-3GlcNAc β 1-3Gal α 1-4Gal β 1-4Glc	100

Gal β 1-4GlcNAc β 1-3Gal α 1-4Gal β 1-4Glc	101
	
NeuAc α 2-3Gal β 1-3GlcNAc β 1-3Gal α 1-4Gal β 1-4Glc	102
	
Fuc α 1-2Gal β 1-3GlcNAc β 1-3Gal α 1-3Gal β 1-4Glc	103
	
L-gulonate linked α (1-4), DP $\approx$ 20 ; M/G ratio<0.25	104
	
L-gulonate linked α (1-4), DP $\approx$ 10 ; M/G ratio<0.25	105
L-gulonate linked α (1-4), DP $\approx$ 5 ; M/G ratio<0.25	106
L-gulonate linked α (1-4), DP $\approx$ 3 ; M/G ratio<0.25	107
D-mannuronate linked β (1-4), DP $\approx$ 20, M/G ratio>4	108
	
D-mannuronate linked β (1-4), DP $\approx$ 10, M/G ratio>4	109
D-mannuronate linked β (1-4), DP $\approx$ 5, M/G ratio>4	110
D-mannuronate linked β (1-4), DP $\approx$ 3, M/G ratio>4	111
D-mannuronate linked β (1-4), DP $\approx$ 30-50, M/G ratio>4	112
D-mannuronate linked β (1-4), DP $\approx$ 20-35, M/G ratio>4	113
D-galacturonate linked α (1-4), DP $\approx$ 25	114
	
D-galacturonate linked α (1-4), DP = 3/4	115
D-galacturonate linked α (1-4), DP = 7/8	116

Oligosaccharides with approx. 80 % GXLF <pre> α-L-Fuc 1 ↓ β-D-Gal 1 ↓ α-D-Xyl α-D-Xyl α-D-Xyl 1 1 1 ↓ ↓ ↓ 6 6 6 β-D-Glc1→4β-D-Glc1→4β-D-Glc1→4β-D-Glc G X L F </pre>	117
Oligosaccharides with approx. 80 % XFG <pre> α-L-Fuc 1 ↓ β-D-Gal 1 ↓ α-D-Xyl α-D-Xyl 1 1 ↓ ↓ 6 6 β-D-Glc1→4β-D-Glc1→4β-D-Glc X F G </pre>	118
Oligosaccharides with approx. 60 % XXFG <pre> α-L-Fuc 1 ↓ β-D-Gal 1 ↓ α-D-Xyl α-D-Xyl α-D-Xyl 1 1 1 ↓ ↓ ↓ 6 6 6 β-D-Glc1→4β-D-Glc1→4β-D-Glc1→4β-D-Glc X X F G </pre>	119
Oligosaccharides with approx. 60 % XLFG <pre> α-L-Fuc 1 ↓ β-D-Gal 1 ↓ α-D-Xyl α-D-Xyl α-D-Xyl 1 1 1 ↓ ↓ ↓ 6 6 6 β-D-Glc1→4β-D-Glc1→4β-D-Glc1→4β-D-Glc X L F G </pre>	120
Glcβ1-4Glc 	121
Glcβ1-4Glcβ1-4Glc 	122
Glcβ1-4Glcβ1-4Glcβ1-4Glc 	123
[Glcβ1-4Glcβ1-4]2Glc 	124
Glcβ1-4[Glcβ1-4Glcβ1-4]2Glc 	125

Glcα1-4Glc 	126
Glcα1-4Glcα1-4Glc 	127
Glcα1-4Glcα1-4Glcα1-4Glc 	128
[Glcα1-4Glcα1-4]₂Glc 	129
Glcα1-4[Glcα1-4Glcα1-4]₂Glc 	130
[Glcα1-4Glcα1-4Glcα1-4]₂Glc 	131
GlcNAcβ1-4GlcNAc 	132
GlcNAcβ1-4GlcNAcβ1-4GlcNAc 	133
GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ1-4GlcNAc 	134
GlcNAcβ1-4[GlcNAcβ1-4]₃Glc 	135

GlcNAcβ1-4[GlcNAcβ1-4GlcNAcβ1-4]₂GlcNAc 	136
[Glcβ1-6Glc]_n, DP $\leq$ 10 	137
[Manβ1-4(Galα1-6)Man]_n, Ratio Man/Gal $\approx$ 2:1 	138
[Manβ1-4Manβ1-4(Galα1-6)Manβ1-4Man]_n, Ratio Man/Gal $\approx$ 4:1 	139
[(Galα1-6)Manβ1-4[(Galα1-6)Man]_n, Ratio Man/Gal $\approx$ 1:1 	140
[Manβ1-4 Manβ1-4(Galα1-6)Manβ1-4Man]_n, Ratio Man/Gal $\approx$ 4:1, DP $\approx$ 3. 	141
[Manβ1-4 Manβ1-4(Galα1-6)Manβ1-4Man]_n, Ratio Man/Gal $\approx$ 4:1, DP $\approx$ 5. 	142
[Manβ1-4 Manβ1-4(Galα1-6)Manβ1-4Man]_n, Ratio Man/Gal $\approx$ 4:1, DP $\approx$ 9. 	143



Man β 1-4(Gal α 1-6)Man β 1-4(Gal α 1-6)Man β 1-4Man β 1-4Man	
	144
[Man β 1-4 Man β 1-4(Gal α 1-6)Man β 1-4Man] _n , Ratio Man/Gal $\approx$ 4:1, DP = 3.	
	145
Man β 1-4Man β 1-4(Gal α 1-6)Man	
	146
Typical polysaccharide motifs: [Glc β 1-4GlcAc β 1-4Man β 1-4Man] _n , Ratio Man/Glc $\approx$ 1/5	
	147
Typical polysaccharide motifs: [Glc β 1-4GlcAc β 1-4Man β 1-4Man] _n	
	148
D-mannose linked β (1-4) (coconuts).	
	149
D-mannose linked β (1-4) partially O-acetylated (<i>Aloe vera</i>)	
D-mannose polysaccharide linked α (1-6) and highly branched with α (1-2) and α (1-3) D-mannose (Yeast).	
D-mannose linked β (1-4), DP = 2 to 24	
Oligosaccharides MW between 3 and 5 kDa (<i>Ulva armoricana</i>)	
Oligosaccharides MW between 1 and 3 kDa (<i>Ulva armoricana</i>)	
Oligosaccharides MW between 0.65 and 1 kDa (<i>Ulva armoricana</i>)	
Oligosaccharides with DP MW 2 to 25 (<i>Palmaria palmata</i>)	
	156



S2 Results of the competitive screening of the 156 glycans toward LecB. Only oligasaccharides having a grade better than E are presented

Family	Sub Family	Structure	Grade	Id
ABO blood ag	H antigenes	Fuca1-2Gal	C	9
		Fuca1-2Gal β 1-4Glc	C	10
		Fuca1-2Gal β 1-3GlcNAc β 1-3Gal	D	11
		Fuca1-2Gal β 1-4GlcNAc β 1-3Gal	D	12
		Fuca1-2Gal β 1-3GlcNAc β 1-3Gal β 1-4Glc	D	13
		Fuca1-2Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc	C	14
		Fuca1-2Gal β 1-3GalNAc β 1-3Gal	C	76
	A antigenes	GalNAc α 1-3(Fuca1-2)Gal	D	15
		GalNAc α 1-3(Fuca1-2)Gal β 1-3GalNAc β 1-3Gal	D	77
Lewis ag	Le ^X antigenes	Gal β 1-4(Fuca1-3)GlcNAc β 1-3Gal	C	26
		Gal β 1-4(Fuca1-3)GlcNAc β 1-3Gal β 1-4(Fuca1-3)Glc	B	27
	Le ^Y antigenes	Fuca1-2Gal β 1-4(Fuca1-3)GlcNAc β 1-3Gal	C	28
	sLe ^X antigenes	Neu5Ac α 2-3Gal β 1-4(Fuca1-3)GlcNAc β 1-3Gal	C	29
	Le ^A antigenes	Gal β 1-3(Fuca1-4)GlcNAc β 1-3Gal	A	30
		Gal β 1-3(Fuca1-4)GlcNAc β 1-3Gal β 1-4(Fuca1-3)Glc	A	31
	Le ^B antigenes	Fuca1-2Gal β 1-3(Fuca1-4)GlcNAc β 1-3Gal	C	32

Fucosylated oligosacch.	"3 fucosyl lactose core"	Gal β 1-4(Fuc α 1-3)Glc	B	33
		Gal β 1-4GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)Glc	B	34
		Gal β 1-3GlcNAc β 1-3Gal β 1-4(Fuc α 1-3)Glc	B	35
		Neu5Ac α 2-3Gal β 1-4(Fuc α 1-3)Glc	B	36
		Gal α 1-3Gal β 1-4(Fuc α 1-3)Glc	B	37
	" 2'3 difucosyl lactose core"	Fuc α 1-2Gal β 1-4(Fuc α 1-3)Glc	C	38
		GalNAc α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-3)Glc	D	39
		Gal α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-3)Glc	D	40
	" 2'2 difucosyl lactose core"	Fuc α 1-2Gal β 1-4(Fuc α 1-2)Glc	C	92
		GalNAc α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-2)Glc	D	93
		Gal α 1-3(Fuc α 1-2)Gal β 1-4(Fuc α 1-2)Glc	D	94
Misc.	Fuc-GM1	Fuc α 1-2Gal β 1-3GalNAc β 1-4(Neu5Ac α 2-3)Gal β 1-4Glc	D	66
	difucosyl-pentaose	Fuc α 1-2Gal β 1-4Glc β 1-1 β Gal α 2-1Fuc	C	90
	Globo-H	Fuc α 1-2Gal β 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc	C	72
	iGbH analogue	Fuc α 1-2Gal β 1-3GlcNAc β 1-3Gal α 1-3Gal β 1-4Glc	D	103

Glucan	Xyloglucan	Main motifs are GXLF (80 %)	C	117
		Main motifs are XFG (80%)	D	118
		Main motifs are XXFG (60%)	D	119
		Main motifs are XLFG (60%)	C	120
Mannan	Mannan	Scaffold consist of D-mannose residues linked $\alpha(1-6)$. D-Mannose side chains linked $\alpha(1-2)$ et $\alpha(1-3)$	A	151







S3 NMR spectra of compounds 165a and 165b.


165a

¹H NMR (300 MHz, Chloroform-d)




¹³C NMR (75 MHz, Chloroform-d)







165b



¹³C NMR (75 MHz, Chloroform-d)




³¹P NMR (121 MHz, Chloroform-d)




S4 characterization for propargylated oligosaccharides: Compounds 166 to 170

Compound 166: Lewis^a tetraose-NAc-propargyl - Gal β 1-3(Fuc α 1-4)GlcNAc β 1-3Gal-NAc-CH₂-CECH




¹H-NMR spectrum




MALDI-TOF positive mode: $M=770$, $m/z=793.282$ $[M+Na]^+$

Compound 167 : Lewis^b pentaose-N-acetyl-propargyl - Fuc α 1-2Gal β 1-3(Fuc α 1-4)GlcNAc β 1-3Gal-NAc-CH₂C $\equiv$ CH




¹H-NMR spectrum




MALDI-TOF positive mode: $M=916$, $m/z=939.361$ $[M+Na]^+$

Compound 168 : 3 fucosyllactose-NAc-propargyl - Gal β 1-4(Fuc α 1-3)Glc-NAc-CH₂-C $\equiv$ CH




¹H-NMR spectrum




MALDI-TOF positive mode: M=567, m/z=590.210 [M+Na]⁺

Compound 169 : Lewis^x tetraose-N-acetyl-propargyl - Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Gal-NAc-CH₂-C $\equiv$ CH




¹H-NMR spectrum




MALDI-TOF positive mode: M=770, m/z=793.278 [M+Na]⁺

Compound 170 : Sialyl Lewis^x pentaose-N-acetyl-propargyl - Neu5α2-3AcGalβ1-4(Fucα1-3)GlcNAcβ1-3GalNAc6S-GlcNAc6S-CH₂-CECH



¹H-NMR spectrum





MALDI-TOF positive mode: M=1083, m/z=1060.388 [M+Na]⁺



S5 Coupling conditions and characterization data for the 50 oligoglycoclusters and the 5 monovalent ligands.



compound	Core	linker	Sequence	Click Method	Amount (nmol)	MALDI- TOF	[M-H] ⁻ MS
						MS Cald	Found
M_LeA		Hex	2	A	10	6167.56	6167.56
M_LeB		Hex	2	A	12	6313.70	6312.91
M_3FL		Hex	5	A	6	5900.31	5900.22
M_LeX		Hex	2	A	8	6167.56	6168.88
M_SLeX		Hex	2	A	10	6458.81	6458.77
G1-LeA	Ara	EG ₂	4	B	6	8506.51	8506.30
G1-LeB	Ara	EG ₂	4	C	4	8944.94	8944.33
G1-3FL	Ara	EG ₂	4	C	7	7896.94	7896.64
G1-LeX	Ara	EG ₂	4	B	5	8506.51	8506.55
G2-LeA	Ara	EG ₄	5	B	7	8770.83	8770.43
G2-LeB	Ara	EG ₄	5	C	6	9209.25	9209.28
G2-3FL	Ara	EG ₄	5	C	12	8161.25	8161.69
G2-LeX	Ara	EG ₄	5	B	4	8770.83	8770.73
G3-LeA	Xylo	EG ₂	2	B	5	8570.56	8570.12
G3-LeB	Xylo	EG ₂	2	C	7	9008.98	9008.59
G3-3FL	Xylo	EG ₂	2	C	9	7960.98	7960.67
G3-LeX	Xylo	EG ₂	2	B	5	8570.56	8570.81
G4-LeA	Xylo	EG ₄	3	B	8	8770.83	8769.89
G4-LeB	Xylo	EG ₄	3	C	7	9209.25	9209.03
G4-3FL	Xylo	EG ₄	3	C	11	8161.25	8161.60
G4-LeX	Xylo	EG ₄	3	B	6	8770.83	8770.63
G5-LeA	Ribo	EG ₂	1	B	4	8506.51	8506.91
G5-LeB	Ribo	EG ₂	1	C	5	8944.94	8945.11
G5-3FL	Ribo	EG ₂	1	C	5	7896.94	7896.15
G5-LeX	Ribo	EG ₂	1	B	2	8506.51	8506.39
G6-LeA	Ribo	EG ₄	3	B	13	8770.83	8770.96
G6-LeB	Ribo	EG ₄	3	B	10	9209.25	9209.31
G6-3FL	Ribo	EG ₄	6	B	5	8161.23	8161.38
G6-LeX	Ribo	EG ₄	3	B	10	8770.83	8770.68
G6-SLeX	Ribo	EG ₄	3	F	6	9644.58	9644.90
G7-LeA	Glc	EG ₂	4	D	5	9406.30	9406.24



G7-LeB	Glc	EG ₂	4	E	8	9990.86	9990.07
G7-3FL	Glc	EG ₂	4	E	9	8593.53	8593.27
G7-LeX	Glc	EG ₂	4	D	4	9406.30	9405.90
G8-LeA	Glc	EG ₄	5	D	6	9758.72	9758.91
G8-LeB	Glc	EG ₄	5	E	9	10343.28	10343.15
G8-3FL	Glc	EG ₄	5	E	5	8945.95	8945.57
G8-LeX	Glc	EG ₄	5	D	4	9758.72	9758.17
G9-LeA	Gal	EG ₂	2	D		9470.34	9470.37
G9-LeB	Gal	EG ₂	2	E	9	10054.91	10055.16
G9-3FL	Gal	EG ₂	2	E	11	8657.57	8657.34
G9-LeX	Gal	EG ₂	2	D	5	9470.34	9470.65
G10-LeA	Gal	EG ₄	3	D	2	9758.72	9758.70
G10-LeB	Gal	EG ₄	3	E	5	10343.28	10344.70
G10-3FL	Gal	EG ₄	3	E	6	8945.96	8945.61
G10-LeX	Gal	EG ₄	3	D	4	9758.72	9757.78
G11-LeA	Man	EG ₂	1	D	4	9406.30	9407.10
G11-LeB	Man	EG ₂	1	E	5	9990.86	9990.28
G11-3FL	Man	EG ₂	1	E	5	8593.53	8593.78
G11-LeX	Man	EG ₂	1	D	3	9406.30	9406.76
G12-LeA	Man	EG ₄	4	D	9	9758.72	9758.30
G12-LeB	Man	EG ₄	4	D	3	10343.28	10343.20
G12-3FL	Man	EG ₄	7	D	9	8964.98	8964.56
G12-LeX	Man	EG ₄	4	D	6	9758.72	9759.02
G12-SLeX	Man	EG ₄	4	G	4	10923.72	10922.53



S6: HPLC chromatograms and MALDI-ToF spectra of oligoglycoclusters with 3-Fucosyl-Lactose (3-FL)










































S7: HPLC chromatograms and MALDI-ToF spectra of oligoglycoclusters with Lewis^a

















zip1.2:CCG CGT TGG ATT AGC



Cal:8570.56



































S8: HPLC chromatograms and MALDI-ToF spectra of oligoglycoclusters with Lewis^b

















Ziptip
HPA



Cal: 9008.98

































S9: HPLC chromatograms and MALDI-ToF spectra of oligoglycoclusters with Lewis^x















Cal: 8770.83


































Cal:9758.72

Ziptip

HPA

Cy3-zip1.4-OH

X:

zip1.4:TGC CAC CTC GCT TGG

S10: HPLC chromatograms and MALDI-ToF spectra of oligoglycoclusters with Sialyl Lewis^x

